8.01
+0.14
+(1.84%)
As of 11:36:23 AM EST. Market Open.
Research Analysis
Earnings Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 5 | 4 | 4 | 5 |
| Avg. Estimate | -0.24 | -0.27 | -1.11 | -0.86 |
| Low Estimate | -0.27 | -0.3 | -1.13 | -0.94 |
| High Estimate | -0.21 | -0.25 | -1.09 | -0.8 |
| Year Ago EPS | -0.3 | -0.32 | -1.38 | -1.11 |
Revenue Estimate
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| No. of Analysts | 7 | 7 | 8 | 8 |
| Avg. Estimate | 46.05M | 46.42M | 177.57M | 210.61M |
| Low Estimate | 43M | 42.49M | 174M | 204M |
| High Estimate | 48M | 48.88M | 179.63M | 217.82M |
| Year Ago Sales | 45.78M | 41.87M | 170.28M | 177.57M |
| Sales Growth (year/est) | 0.58% | 10.87% | 4.28% | 18.61% |
Earnings History
| Currency in USD | 12/31/2023 | 3/31/2024 | 6/30/2024 | 9/30/2024 |
|---|---|---|---|---|
| EPS Est. | -0.33 | -0.34 | -0.33 | -0.27 |
| EPS Actual | -0.3 | -0.32 | -0.29 | -0.22 |
| Difference | 0.02 | 0.02 | 0.04 | 0.05 |
| Surprise % | 6.99% | 6.15% | 12.02% | 19.84% |
EPS Trend
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Current Estimate | -0.24 | -0.27 | -1.11 | -0.86 |
| 7 Days Ago | -0.24 | -0.27 | -1.11 | -0.86 |
| 30 Days Ago | -0.24 | -0.26 | -1.11 | -0.85 |
| 60 Days Ago | -0.27 | 0 | -1.11 | -0.88 |
| 90 Days Ago | -0.28 | -0.27 | -1.23 | -0.89 |
EPS Revisions
| Currency in USD | Current Qtr. (Dec 2024) | Next Qtr. (Mar 2025) | Current Year (2024) | Next Year (2025) |
|---|---|---|---|---|
| Up Last 7 Days | 1 | -- | -- | -- |
| Up Last 30 Days | 5 | -- | 3 | -- |
| Down Last 7 Days | -- | 1 | -- | 1 |
| Down Last 30 Days | -- | 1 | -- | 1 |
Growth Estimates
| Current Qtr. | Next Qtr. | Current Year | Next Year | |
|---|---|---|---|---|
| ADPT | 19.88% | 15.28% | 19.75% | 22.34% |
| S&P 500 | 9.91% | 10.33% | 14.01% | 13.75% |
Upgrades & Downgrades
| Maintains | Goldman Sachs: Neutral to Neutral | 1/28/2025 |
| Maintains | BTIG: Buy to Buy | 12/18/2024 |
| Maintains | Piper Sandler: Overweight to Overweight | 11/11/2024 |
| Maintains | BTIG: Buy to Buy | 10/2/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 8/2/2024 |
| Maintains | JP Morgan: Overweight to Overweight | 5/8/2024 |
Related Tickers
BEAM Beam Therapeutics Inc.
27.43
+0.55%
FATE Fate Therapeutics, Inc.
1.3450
-1.82%
VERV Verve Therapeutics, Inc.
7.71
+3.99%
NTLA Intellia Therapeutics, Inc.
10.52
+0.10%
CDXS Codexis, Inc.
4.4000
-2.22%
VIR Vir Biotechnology, Inc.
10.35
+0.39%
EDIT Editas Medicine, Inc.
1.3650
-0.36%
ABSI Absci Corporation
3.7901
-0.78%
CRBU Caribou Biosciences, Inc.
1.4650
+11.83%
COGT Cogent Biosciences, Inc.
9.54
-0.83%